Outlook Therapeutics, Inc.
ONS-5010
wet age-related macular degeneration (wet AMD)
Resolved
140days ago
Catalyst readout · Feb 17, 2026
What's at stake
A key catalyst for ONS-5010 (wet age-related macular degeneration (wet AMD)) is expected Feb 17, 2026.
Primary source
· SEC 8-K
verified 14h ago
“Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., February 17, 2026”